MSME (Udyam registered) Ministry of MSME
- Category
- Medium (2024-25)
- Udyam number
- UDYAM-MH-19-0019025
Naxpar Pharma Private Limited - pharma in Mumbai, Maharashtra, India. FY 2026 financials & compliance.
Revenue · FY 2025
₹183.89 Cr
▲ 1% YoY
Net profit · FY 2025
₹10.14 Cr
Net margin 5.5%
EBITDA · FY 2025
₹26.98 Cr
EBITDA margin 14.7%
Authorised capital
₹5 Cr
Registered with MCA
Paid-up capital
₹5 Cr
Issued & subscribed
Open charges
₹125.65 Cr
Satisfied ₹17.47 Cr
Company age
22 yrs
Est. 2004
Employees · EPFO
448
Provident fund records
About Naxpar Pharma Private Limited
Data last updated:
Naxpar Pharma Private Limited is a private limited company based in Mumbai, Maharashtra, India, a subsidiary of Parnax Lab Limited. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 10 February 2004 and has been in existence for over 22 years.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN U52310MH2004PTC144449. Its GSTIN is 27AADCP2044D1ZU (Maharashtra). The company holds 4 GST registrations, of which 3 are active.
The company has an authorised share capital of ₹5 Cr and a paid-up capital of ₹5 Cr. It was formerly known as Parav Biopharm Private Limited. It is led by directors including Mihir Prakash Shah (Whole-Time Director) and Baiju Mahasukhlal Shah (Whole-Time Director).
Its last annual general meeting (AGM) was held on 26 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at 104 – 107 Bldg No 8 Jogani Ind Complex Chunabhatti, Mumbai, Maharashtra, India – 400022.
As per the financials filed for FY 2025, the company reported a revenue of ₹183.89 Cr, a growth of 1% compared to the previous year. For the same year it recorded a net profit of ₹10.14 Cr (net margin 5.5%) and EBITDA of ₹26.98 Cr (EBITDA margin 14.7%). Revenue has grown at a compounded annual rate (CAGR) of 5% over three years and 15% over five years.
The company has about 448 employees on its provident fund (EPFO) records.
As per MCA filings, the company has open charges of ₹125.65 Cr and satisfied charges of ₹17.47 Cr on record. Court records list 14 cases involving the company, including 8 filed by the company and 6 filed against it; 3 cases are pending. The company has 1 deal on record (1 funding round), with disclosed funding of ₹9.98 Cr; the latest was in April 2007. Its 8 peer companies in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 4 larger and 4 smaller; the largest is Regenix Drugs Limited with revenue of ₹188.37 Cr. The company has 23 MSME Form 1 returns on record between 2017 and 2024, listing 2,787 overdue payments to 169 micro and small suppliers.
Naxpar Pharma Private Limited is registered as a medium enterprise under the Udyam registration framework (Reg. No. UDYAM-MH-19-0019025). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website naxparlab.com.
Company details
CIN U52310MH2004PTC144449
Registration Number 144449
Incorporation Date 10 February 2004
ROC Mumbai
Listing Status Unlisted
Company Status Active
Date of Last AGM 26 September 2025
Date of Balance Sheet 31 March 2025
Parent Company Parnax Lab Limited
Compliance Status Active Compliant
MSME Classification Medium
Udyam Registration UDYAM-MH-19-0019025
Key People
Mihir Prakash Shah Whole-Time Director Baiju Mahasukhlal Shah Whole-Time Director Prakash Mahasukhlal Shah Whole-Time Director Recognitions & Rankings of Naxpar Pharma
Contact details
Naxpar Pharma Private Limited's registered office is in Mumbai, Maharashtra. Its website is naxparlab.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered Address104 – 107 Bldg No 8 Jogani Ind Complex Chunabhatti, Mumbai, Maharashtra, India – 400022
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Naxpar Pharma Private Limited, buy the company report.
Comprehensive company report
Naxpar Pharma Private Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Business activity
The main business activity of Naxpar Pharma is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Naxpar Pharma Private Limited, buy the company report.
Financials of Naxpar Pharma Private Limited
FY 2025 filings availableNaxpar Pharma Private Limited reported revenue of ₹183.89 Cr (up 1% YoY) for FY 2025.
Revenue · FY 2025
₹183.89 Cr ▲ 1%
Net profit · FY 2025
₹10.14 Cr margin 5.5%
EBITDA · FY 2025
₹26.98 Cr margin 14.7%
Compounded Annual Growth Rate (CAGR)
Revenue CAGR growth
1 year
▲ 1%
3 years · compounded
▲ 5%
5 years · compounded
▲ 15%
EBITDA CAGR growth
1 year
▲ 23%
3 years · compounded
▲ 7%
5 years · compounded
▲ 34%
Revenue has grown at a compounded annual rate (CAGR) of 15% over five years, including 1% growth in the latest year. EBITDA rose 23% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹26.98 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹10.14 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 14.7% | ||||
| Net Profit Margin | 5.5% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Naxpar Pharma Private Limited, buy the company report.
Board of directors of Naxpar Pharma Private Limited
Naxpar Pharma has 5 current directors and 8 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Harish Sunderlal Panpalia Also directs: Parnax Lab Limited | Director | 11 Aug 2023 | 3 Years 2 Months | Current |
| Mihir Prakash Shah Also directs: Parnax Lab Limited, Novomed Pharma Pvt. Ltd | Whole-Time Director | 10 Feb 2004 | 22 Years 8 Months | Current |
| Yogesh Kantilal Varia Also directs: Parnax Lab Limited | Director | 28 May 2021 | 5 Years 4 Months | Current |
| Baiju Mahasukhlal Shah | Whole-Time Director | 10 Feb 2004 | 22 Years 8 Months | Current |
| Prakash Mahasukhlal Shah | Whole-Time Director | 10 Feb 2004 | 22 Years 8 Months | Current |
Peer comparison
Naxpar Pharma Private Limited is compared with the 8 companies closest to it by revenue in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Regenix Drugs Limited | ₹188.37 Cr (FY 2024) | 9.0% | Chennai, Tamil Nadu, India | |||
| Goldencross Pharma Limited | ₹187.87 Cr (FY 2025) | 31.0% | Mumbai, Maharashtra, India | |||
| Comed Chemicals Limited | ₹187.35 Cr (FY 2025) | 12.0% | Vadodara, Gujarat, India | |||
| Mapra Laboratories Pvt Ltd | ₹184.45 Cr (FY 2025) | 5.0% | Mumbai, Maharashtra, India | |||
| Naxpar Pharma Private Limitedthis company | ₹183.89 Cr (FY 2025) | ₹10.14 Cr | 5.5% | 1.0% | 448 | Mumbai, Maharashtra, India |
| Infutec Healthcare Limited | ₹183.11 Cr (FY 2021) | -22.0% | Mumbai, Maharashtra, India | |||
| Sakar Healthcare Limited | ₹178.9 Cr (FY 2025) | 14.0% | Changodar, Gujarat, India | |||
| Stanford Laboratories Private Ltd | ₹178.12 Cr (FY 2025) | 3.0% | New Delhi, Delhi, India | |||
| BDR Lifesciences Private Limited | ₹176.87 Cr (FY 2025) | -5.0% | Vadodara, Gujarat, India |
To see the full peer comparison of Naxpar Pharma Private Limited, buy the company report.
Auditor
Naxpar Pharma Private Limited is audited by Ladha Singhal And Associates for the financial year 2024.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| Ladha Singhal And Associates | FY 2024 | 120241W |
Shareholding
The shareholding of Naxpar Pharma Private Limited is on record for 5 financial years, the latest being FY 2024, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2024 | FY 2023 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Naxpar Pharma Private Limited, buy the company report.
Charges & borrowings
Open charges
₹125.65 Cr
Satisfied charges
₹17.47 Cr
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 30 Jun 2025 | 101152586 | Hdfc Bank Limited | ₹2.91 Cr | Open | |
| 13 Dec 2023 | 100835802 | Hdfc Bank Limited | ₹14.16 Cr | Open | |
| 25 Jul 2023 | 100812836 | Hdfc Bank Limited | ₹9.77 Lakh | Open | |
| 24 Dec 2021 | 100535715 | Others | ₹4 Cr | Open | |
| 29 Oct 2021 | 100517503 | Hdfc Bank Limited | ₹78.91 Lakh | Open |
To see the full charge records of Naxpar Pharma Private Limited, buy the company report.
Total charge records: 20 View all charges
Deals & funding
Naxpar Pharma Private Limited has 1 deal on record (1 funding round), with disclosed funding of ₹9.98 Cr; the latest was in April 2007.
Total deals
1
Funding round
1
Disclosed funding
₹9.98 Cr
Deals on record (1 of 1)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Apr 2007 | Funding round | ₹9.98 Cr | Investors: Pamax Lab Private Limited |
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Naxpar Pharma Private Limited has 14 court cases on record: 8 filed by Naxpar Pharma, 6 filed against it. 3 cases are pending and 11 are disposed.
Total cases
14
Filed by the company
8
Filed against the company
6
Pending
3
Disposed
11
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 7 | 5 | 2 |
| NCLAT | 3 | 0 | 0 |
| High courts | 2 | 0 | 1 |
| Supreme Court | 2 | 1 | 0 |
Cases on record (5 of 14)
| Court | Type of case | Party | Status |
|---|---|---|---|
| High Court, HIMACHAL PRADESH | Writ petition | Filed by the company against Himachal Pradesh State Electricity Board Ltd. and 2 others | Disposed |
| Supreme Court | Court case (1006-Company Law, Mrtp, Trai, Sebi, Idrai & Rbi : Others) | Filed by the company against Sanjai Kumar Gupta Present Resolution Professional of Stone India Limited (Kuldeep Verma Erstwhile Interim Resolution Professional A-6, Charulata Pally, ,Kolkata , West Bengal | Disposed |
| District court, South Twenty Four Parganas, West Bengal | Civil suit | Filed against the company by Emami Ltd. | Disposed |
| High Court, HIMACHAL PRADESH | Interim or miscellaneous application | Filed by the company against State of HP and Others(Not Applicable) | Pending |
| District court, Ahmedabad, Gujarat | Commercial matter | Filed by the company against an individual | Pending |
To see the full case history of Naxpar Pharma Private Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
Naxpar Pharma Private Limited has 23 MSME Form 1 returns on record between 2017 and 2024, listing 2,787 overdue payments to 169 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 169)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| an individual supplier | |||
| an individual supplier | |||
| an individual supplier | |||
| an individual supplier | |||
| an individual supplier |
To see the full MSME payment records of Naxpar Pharma Private Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Employees & EPFO
Naxpar Pharma Private Limited has a workforce of 448 employees on its EPFO records as of Mar 21, 2024, across 1 active EPFO establishment.
Employee count
448
Active EPFO establishments
1
Employee growth
10.62%
GST
Naxpar Pharma has 4 GST registrations: 3 active and 1 cancelled or inactive.
Total GSTINs
4
Active
3
Cancelled / inactive
1
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AADCP2044D1ZU | Maharashtra | Active | 01 Jul 2017 |
| 27AADCP2044D2ZT | Maharashtra | Active | 16 Aug 2017 |
| 02AADCP2044D1Z6 | Himachal Pradesh | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Naxpar Pharma Private Limited, buy the company report.
Recent activity
Naxpar Pharma Private Limited has 12 board changes on record since 2004: 5 appointments and 7 cessations. The latest: Harish Sunderlal Panpalia ceased to be Additional Director on 28 Sep 2023.
AGM
Naxpar Pharma Private Limited last Annual general meeting of members was held on 26 Sep 2025 as per latest MCA records.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 2.91 Cr with Charge ID 101152586 was registered on 30 Jun 2025.
Charges
A charge registered on 20 Jun 2020 via Charge ID 100396236 with Hdfc Bank Limited was fully satisfied on 08 Jun 2025.
Filing
Naxpar Pharma Private Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Mumbai.
Charges
A charge with Others of Rs. 23.77 Cr registered on 30 Jan 2021 with Charge ID 100417613 was modified on 12 Sep 2024.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 14.16 Cr with Charge ID 100835802 was registered on 13 Dec 2023.
Ceased
Harish Sunderlal Panpalia ceased to be Additional Director.
Appointed
Harish Sunderlal Panpalia was appointed as Director.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 0.10 Cr with Charge ID 100812836 was registered on 25 Jul 2023.
Charges
A charge with Others amounted to Rs. 4.00 Cr with Charge ID 100535715 was registered on 24 Dec 2021.
Charges
A charge with Others of Rs. 6.00 Cr registered on 08 Jun 2021 with Charge ID 100450178 was modified on 16 Dec 2021.
Ceased
Yogesh Kantilal Varia ceased to be Additional Director.
36 earlier events are in the company report.
Frequently asked questions
Naxpar Pharma is an active private limited company based in Mumbai, Maharashtra, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 10 February 2004 (22+ years old) and is registered under CIN U52310MH2004PTC144449.
Naxpar Pharma has 5 current directors:
- Mihir Prakash Shah - Whole-Time Director
- Baiju Mahasukhlal Shah - Whole-Time Director
- Prakash Mahasukhlal Shah - Whole-Time Director
- Harish Sunderlal Panpalia - Director
- Yogesh Kantilal Varia - Director
The latest financial statements of Naxpar Pharma on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 26 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Naxpar Pharma is 27AADCP2044D1ZU, registered in Maharashtra. The company has 4 GST registrations in all, of which 3 are active and 1 is cancelled or inactive. Other active GSTINs include 27AADCP2044D2ZT (Maharashtra), 02AADCP2044D1Z6 (Himachal Pradesh).
The CIN (Corporate Identification Number) of Naxpar Pharma is U52310MH2004PTC144449. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Naxpar Pharma has 14 court cases on record: 8 filed by the company and 6 filed against it. 3 are pending. Most are in the district courts.
Naxpar Pharma was incorporated on 10 February 2004, making it 22+ years old. It is registered with the Registrar of Companies, Mumbai.
Naxpar Pharma has 1 deal on record (1 funding round), with disclosed funding of ₹9.98 Cr; the latest was in April 2007.
The peers of Naxpar Pharma by revenue are Regenix Drugs Limited, Goldencross Pharma Limited, Comed Chemicals Limited, Mapra Laboratories Pvt Ltd, Infutec Healthcare Limited and 3 more, all in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Harish Sunderlal Panpalia ceased to be Additional Director on 28 Sep 2023. Harish Sunderlal Panpalia was appointed as Director on 11 Aug 2023. Yogesh Kantilal Varia ceased to be Additional Director on 30 Nov 2021. Naxpar Pharma has 12 board changes on record in total.
Yes, Naxpar Pharma is registered as a medium enterprise under Udyam registration (number: UDYAM-MH-19-0019025).
Naxpar Pharma has 23 MSME Form 1 returns on record between 2017 and 2024, listing 2,787 overdue payments to 169 micro and small suppliers. The latest return was filed on 30 Apr 2024.